Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01872533 · ClinicalTrials.gov registry record · Early Phase 1
Effect of 10-day Overnight Hypoxia Treatment on Whole Body Insulin Sensitivity (SLEEP HIGH Study)
A Early Phase 1 study of Insulin Resistance, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01872533: Completed Early Phase 1 study of Insulin Resistance, sponsored by Pennington Biomedical Research Center.
NCT01872533 is a Early Phase 1 study of Insulin Resistance that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 9 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01872533, a Early Phase 1 study of Insulin Resistance, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to look at how a reduction in oxygen levels (hypoxia) influences insulin sensitivity and carbohydrate metabolism. It is expected that 10 nights of exposure to moderate hypoxia (\~ 15% O2, similar to conditions at an altitude of \~7500 feet) will improve glucose metabolism.
Primary Outcome
Glucose disposal and oxidation were measured using a two-step hyperinsulinemic euglycemic clamp and indirect calorimetry.
Conditions Studied
Interventions
- OTHER Hypoxia Exposure
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-05 |
| Phase | Early Phase 1 |
What the finished NCT01872533 record still lists
NCT01872533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which Hypoxia Exposure is the first listed.
NCT01872533 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT01872533 about?
NCT01872533 is a clinical study titled "Effect of 10-day Overnight Hypoxia Treatment on Whole Body Insulin Sensitivity (SLEEP HIGH Study)". The purpose of this study is to look at how a reduction in oxygen levels (hypoxia) influences insulin sensitivity and carbohydrate metabolism. It is expected that 10 nights of exposure to moderate hypoxia (\~ 15% O2, similar to conditions at an altitude of \~7500 feet) will improve glucose metabolis...
What is the current status of trial NCT01872533?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2011-07. Estimated completion is 2013-05.
What conditions does trial NCT01872533 study?
This clinical trial studies the following conditions: Insulin Resistance.
What interventions are being tested in trial NCT01872533?
The interventions under investigation include: Hypoxia Exposure (OTHER).
Who is sponsoring clinical trial NCT01872533?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01872533 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01872533's enrollment target sits among peer trials
9 114th of 120 higher than 6 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Role of Metformin on Muscle Health of Older Adults
ACTIVE NOT RECRUITING · Early Phase 1
-
Low Dose Fat-Induced Insulin Resistance
COMPLETED · Early Phase 1
-
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)
COMPLETED · Early Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia